<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674462</url>
  </required_header>
  <id_info>
    <org_study_id>20-01782</org_study_id>
    <nct_id>NCT04674462</nct_id>
  </id_info>
  <brief_title>Understanding Poor Vaccine Responses to Hepatitis B Vaccination</brief_title>
  <official_title>Understanding Poor Vaccine Responses to Hepatitis B Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccines have prevented countless infections but poor vaccine responses remain a major&#xD;
      challenge in many scenarios. Hepatitis B vaccine nonresponses are common but immunologically&#xD;
      not well-understood.&#xD;
&#xD;
      This study aims to study the immunology of hepatitis B vaccine responses by comparing&#xD;
      traditional HBV vaccine, which is associated with nonresponses in some patients, to&#xD;
      CpG-adjuvanted HBV vaccine, which is associated with far fewer rates of nonresponses. This&#xD;
      research will build upon prior studies of the human immune response to infection to gain a&#xD;
      deeper understanding of the complexity of these responses. This information will be broadly&#xD;
      useful as many vaccine candidates fail due to lack of immunogenicity, potentially enabling&#xD;
      improved vaccine design and better protection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Weak Vaccine Response</measure>
    <time_frame>Month 1 Post-Final Dose</time_frame>
    <description>Weak vaccine response is defined as Hepatitis B surface antigen antibodies &lt;= 10 mIU/mL (i.e. plasma anti-Hepatitis B surface antibody titer that is undetectable or below the cuff)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vaccine Reaction</condition>
  <arm_group>
    <arm_group_label>CpG-adjuvanted HBV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional HBV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CpG-adjuvanted HBV Vaccine</intervention_name>
    <description>Subjects receiving CpG-adjuvanted HBV vaccine will require two doses at 0 and 1 month after initiation. The second dose will be considered the same as the one month time point following the first dose.</description>
    <arm_group_label>CpG-adjuvanted HBV Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Traditional HBV Vaccine</intervention_name>
    <description>Subjects receiving traditional HBV vaccine series will require three doses at 0, 1, and 6 months after initiation. The second dose will be considered the same as the one month time point following the first dose.</description>
    <arm_group_label>Traditional HBV Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age&#xD;
&#xD;
          2. Must be able to understand and sign the Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known chronic HBV infection&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Known clinically significant anemia or contraindication to phlebotomy; i.e.,&#xD;
             anti-coagulation therapy or clinically significant thrombocytopenia&#xD;
&#xD;
          4. Any condition that, in the opinion of the Investigator, would make study participation&#xD;
             unsafe or would interfere with the objectives of the study&#xD;
&#xD;
          5. Use of immune-suppressing medications in the 30 days prior to enrollment HIV/AIDS&#xD;
             patients will be included in the study as these patients often have poor responses to&#xD;
             HBV vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramin Herati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramin Herati, MD</last_name>
    <phone>646-477-9086</phone>
    <email>Ramin.Herati@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Raabe, MD, MSc</last_name>
    <email>Vanessa.raabe@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ramin Herati, MD</last_name>
      <email>Ramin.Herati@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Raabe, MD, MSc</last_name>
      <email>Vanessa.Raab@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ramin Herati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Mulligan, MD, FIDSA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Raabe, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to ramin.herati@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

